No Data
Guangdong Vtr Bio-Tech (300381.SZ): plans to launch a restricted stock incentive plan for 2025.
Gelonghui reported on February 19 that Guangdong Vtr Bio-Tech (300381.SZ) announced the draft of the 2025 restricted stock incentive plan. The total number of restricted stocks proposed to be granted to the incentive recipients is 6.5 million shares, accounting for 1.32% of the company's total share capital of 491.061461 million shares on the date of the announcement of this incentive plan draft. Among them, the initial proposed grant is 5.46 million shares, accounting for 1.11% of the company's total share capital at the time of the announcement of this incentive plan draft, which constitutes 84.00% of the total number of restricted stocks granted under this incentive plan; 1.04 million shares are reserved, accounting for 0.21% of the company's total share capital at the time of the announcement of this incentive plan draft.
Profit: 2024 Annual Results Forecast
VTR Bio-Tech to Redeem Convertible Bonds of 665 Million Yuan
Guangdong Vtr Bio-Tech (300381.SZ): Jindadi Investment has cumulatively reduced its shareholding by 1.94%.
On December 15, Gelonghui reported that Guangdong Vtr Bio-Tech (300381.SZ) announced that on December 13, 2024, the company received a notice from Jinda Di Investment regarding the completion of the shareholding reduction plan. On December 12, 2024, Jinda Di Investment reduced its shareholding by 720,000 shares through a block trade, accounting for 0.15% of the company's total share capital after deducting shares held in the company's repurchase special securities account. As of the date of this announcement, Jinda Di Investment has cumulatively reduced its shareholding by 9,309,000 shares, accounting for 1.94% of the company's total share capital after deducting shares held in the company's repurchase special securities account.
Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Largest Shareholders Are Retail Investors Who Were Rewarded as Market Cap Surged CN¥398m Last Week
Profit: Report for the third quarter of 2024
Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Not Doing Enough For Some Investors As Its Shares Slump 27%